Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966982 | 0.95 | LMNA (0.44) | CNR2KDM4ELMNASMN1; SMN2ALOX15 | |
| SCHEMBL4969466 | 0.90 | CNR2 (0.46) | CNR2KDM4ELMNASMN1; SMN2ALOX15 | |
| SCHEMBL4967074 | 0.89 | KDM4E (0.47) | CNR2KDM4ELMNASMN1; SMN2ALOX15 | |
| SCHEMBL4965882 | 0.85 | PAX8 (0.50) | LMNASMN1; SMN2HTTPKML3MBTL1 | |
| SCHEMBL4974554 | 0.83 | KDM4E (0.46) | CNR2KDM4ELMNASMN1; SMN2ALOX15 | |
| SCHEMBL4966290 | 0.82 | CNR2 (0.55) | CNR2 | |
| SCHEMBL4966095 | 0.80 | CNR2 (0.62) | CNR2 | |
| SCHEMBL4965533 | 0.79 | CNR2 (0.64) | CNR2 | |
| SCHEMBL4967702 | 0.78 | CNR2 (0.58) | CNR2 | |
| SCHEMBL5722145 | 0.77 | KDM4E (0.49) | CNR2KDM4ELMNAPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | CNR2 697/4885KDM4E 1841/4885LMNA 2120/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | CNR2 202/4885KDM4E 2030/4885LMNA 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.